Methods for treatment of cancer with an anti-tigit antagonist antibody
US-2024424092-A1 · Dec 26, 2024 · US
US2025076311A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2025076311-A1 |
| Application number | US-202418929733-A |
| Country | US |
| Kind code | A1 |
| Filing date | Oct 29, 2024 |
| Priority date | Dec 19, 2014 |
| Publication date | Mar 6, 2025 |
| Grant date | — |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The disclosure provides anti-myostatin antibodies and methods of making and using the same. Nucleic acids encoding the anti-myostatin antibodies and host cells comprising the nucleic acids are also provided. The anti-myostatin antibodies have uses that include treating a muscle wasting disease, reducing body fat accumulation, and increasing mass and strength of muscle tissue. The disclosure also provides polypeptides containing a variant Fc region and methods of making and using the same. Nucleic acids encoding the polypeptides and host cells comprising the nucleic acids are also provided. The polypeptides have uses that include suppressing the activation of immune cells; treating an immunological inflammatory disease, autoimmune disease, or viral infection; and increasing muscle mass and strength or reducing body fat accumulation.
Opening claim text (preview).
1 - 54 . (canceled) 55 . A method of treating an individual having an adipose tissue disorder comprising administering to the individual an effective amount of an antibody that binds to latent myostatin. 56 . The method of claim 55 , wherein the antibody blocks the release of mature myostatin from latent myostatin. 57 . The method of claim 55 , wherein the antibody does not bind to mature myostatin. 58 . The method of claim 55 , wherein the antibody binds to latent myostatin with higher affinity at neutral pH than at acidic pH. 59 . The method of claim 55 , wherein the antibody is a full-length IgG antibody.
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Complementarity determining region [CDR] · CPC title
Constant or Fc region; Isotype · CPC title
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
Cells for production · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.